VA-REGULA
15.2.2024 08:01:33 CET | Business Wire | Press release
Frost & Sullivan recognizes companies with Best Practices Awards in various categories for outstanding efforts to inspire growth in their industries. Businesses that earn these awards identify emerging trends before they become the market standard and create solutions that drive differentiation and sustainable growth. Frost & Sullivan considers these companies to be the game changers.
As for the Enabling Technology Leadership Award in the identity verification (IDV) industry, Frost & Sullivan applies a rigorous analytical process to assess multiple nominees. This involves a detailed evaluation of best practices criteria across two dimensions: Technology Leverage and Customer Impact. Frost & Sullivan points out that Regula excels in many of the criteria in the IDV solutions space.
Synergizing cutting-edge verification technologies with an intuitive user-centric design. Experts emphasize Regula's product portfolio, seamlessly integrating a single-vendor solution for complete identity verification based on biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with enhanced authenticity validation, along with forensic devices dedicated to in-depth examination. At the heart of Regula’s IDV solution lies the most comprehensive database encompassing over 13,500 documents from 247 countries and territories, supporting over 138 languages.
Regula distinguishes itself by fostering innovation through in-house development of all technologies, steering clear of third-party dependencies. Notably, its standout feature is the platform-agnostic nature of its digital identification solutions. This enables customers to orchestrate an enhanced ID verification process effortlessly on any platform—be it mobile, web, desktop platforms, or passport readers.
Forging strategic alliances with renowned international organizations. Regula forges strategic partnerships with esteemed organizations like the International Air Transport Association, International Organization for Migration, and International Civil Aviation Organization. This collaborative effort establishes Regula as an integral player in a symbiotic exchange of insights and vital information about documents. This ongoing collaboration serves as a catalyst for continuously refining its technologies, positioning the company at the forefront of innovation.
Transforming customer workflows in many industries through value-driven verification solutions. Regula's distinctive offering lies in its rich heritage in the forensics space. The one-stop-shop nature of Regula’s solutions eradicates the necessity for customers to enlist multiple vendors for additional security measures and ensures a comprehensive strategy addressing security, forensics, and identity verification requirements in a seamless and integrated manner.
Enduring excellence through long-term customer relationships. Regula’s value-driven identity verification solutions extend across a spectrum of industry verticals, including banking, fintech, aviation, telecommunication, government authorities, healthcare, insurance, forensic labs, gambling, and others. The company's achievements are evidenced by providing hardware and software solutions for digital identity verification to a global network of over 1,000 organizations and 80 border control authorities. Notably, Regula's clientele includes major players such as the largest private bank globally, and prominent airline companies like AirAsia and WizzAir. Also, Regula has solidified its position as a trusted technology partner for several years at the Mobile World Congress (MWC), a premier international industry event organized by the GSMA.
On top of this, Frost & Sullivan believes Regula outperforms in responding to the complex landscape of identity fraud. Rabin Dhakal, Frost & Sullivan Best Practices Research Analyst states: “In the face of an escalating wave of sophisticated fraud, identity theft, and scams, the urgency for a robust identity verification solution has never been more pronounced. Frost & Sullivan believes that Regula’s proactive response to the evolving landscape of document fraud and fakes is unprecedented.”
"We are truly honored to be acknowledged by a prominent expert in market growth and innovations. We strive to emphasize the key differentiator for Regula, which lies in the wealth of experience gained over three decades - specifically in understanding documents and verification processes, our comprehensive document template database, full-cycle in-house production, and the team of top-notch forensic experts. These are the assets that enable us to drive continuous innovation and provide a comprehensive solution to identity verification,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the 2024 Frost & Sullivan Global Enabling Technology Leadership Award in the identity verification solutions industry, please read the report.
About Frost & Sullivan
Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO's growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214825831/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
